Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies Migraine affects up to 40 % of people with multiple sclerosis (PwMS). This study aimed to evaluate the effectiveness and safety of the combination of antibodies (mAbs) against CGRP (anti-CGRP mAbs) with disease-modifying treatments (DMTs) for MS (mAb and non-mAbs) and their impact on MS disease course.
https://www.jns-journal.com/ar....ticle/S0022-510X(25)